NCT02460588View on ClinicalTrials.gov

Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

January 31, 2019

Study Completion Date

July 31, 2019

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Cyclophosphamide

"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"

DRUG

Placebo

Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.

DRUG

Corticosteroid (prednisolone)

All patients will receive non experimental medication with high dose of corticosteroid.

Trial Locations (1)

Unknown

Hôpital Tenon, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02460588 - Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter